NewEdge Advisors’s Cocrystal Pharma COCP Stock Holding History

NewEdge Advisors’s Portfolio COCP Stock Details COCP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-18	Closed	-$35	–	3547
2022 Q4	$35	Buy	+18	New	+$46	﹤0.01%	3519

Other funds holding COCP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

NewEdge Advisors's COCP Position: Q1 2023 in Review

NewEdge Advisors sold out of Cocrystal Pharma (COCP) in Q1 2023, closing a stake of 18 shares — an estimated $35 sold.

NewEdge Advisors first reported a position in COCP in Q4 2022 and held it in 1 quarter. The position peaked at $35 in Q4 2022. 21 funds tracked by Wall St. Rank hold COCP as of Q1 2023.

NewEdge Advisors reported no remaining Cocrystal Pharma position as of Q1 2023 after selling out during the quarter.
NewEdge Advisors sold 18 Cocrystal Pharma shares in Q1 2023, an estimated $35.
NewEdge Advisors first reported a position in Cocrystal Pharma in Q4 2022 and held it in 1 quarter.
NewEdge Advisors's Cocrystal Pharma position peaked at $35 in Q4 2022.
21 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q1 2023.

Based on NewEdge Advisors's 13F filing for Q1 2023, filed 12 May 2023.